The Fas/FasL system transmits intracellular apoptotic signaling, inducing cell apoptosis. However, Fas signaling also exerts non-apoptotic functions in addition to inducing tumor cell apoptosis. For example, Fas signaling induces lung cancer tumor cells to produce prostaglandin E2 (PGE2) and recruit myeloid-derived suppressor cells (MDSCs). Activated cytotoxic T lymphocytes (CTLs) induce and express high levels of FasL, but the effects of Fas activation initiated by FasL in CTLs on apoptosis-resistant tumor cells remain largely unclear. We purified activated CD8
INTRODUCTION
Some tumors can escape attack from the immune system of the body, a process that is called tumor escape. Active T cells play a key role in antitumor escape. In particular, cytotoxic T lymphocytes (CTLs) are important effector cells involved in eliminating tumor cells. 1 However, some tumor tissues are infiltrated by terminally differentiated cytotoxic T lymphocytes that exist in an unresponsive state. 1, 2 The role of these infiltrating CTLs in tumor progression is unclear. During T-cell activation, increased FasL expression on activated CTL cell surfaces renders CTLs able to kill tumor cells and induce auto-apoptosis. In the presence of extensive lung metastases, Fas/FasL signaling plays an important role in CTL-prompted tumor regression. 3 However, in CTL-based immunotherapy, tumor cells are unresponsive to tumor infiltrating lymphocytes (TILs) and thus, the susceptibility of tumor cells to Fasmediated cytotoxicity is diminished, ultimately leading to tumor escape. Our previous work showed that exosomes derived from activated T cells promoted tumor invasion via the Fas signaling pathway. 4 In the present study, we investigated whether Fas signaling initiated by FasL expressed on infiltrating CTLs has a negative effect on the immune response of Fas-resistant tumor cells, thus causing tumor escape during tumor development and progression.
The death receptor Fas (CD95/APO-1) is a member of a tumor growth factor receptor superfamily. After Fas is triggered by its natural ligand, FasL, Fas signaling transmits intracellular apoptotic signals and leads to the apoptosis of cells to maintain systematic homeostasis. 5 However, under certain conditions, Fas signaling can exert non-apoptotic effects, including inflammatory responses, liver regeneration, increased branching of developing neurons, migration of cells, angiogenesis, fibrosis, proliferation and differentiation of cells and advancement of the cell cycle. [6] [7] [8] [9] [10] [11] Therefore, although almost all tumor cells express the Fas receptor, the Fas pathway may also be beneficial to tumor cell survival rather than apoptosis. 6, [8] [9] [10] Activation of Fas signaling in the Lewis lung cancer cell line (3LL cells) does not cause apoptosis but induces 3LL cells to secrete more prostaglandin E2(PGE2). 12 High levels of PGE2 aid 3LL cells in recruiting myeloid-derived suppressor cells (MDSCs), leading to tumor cell escape. 13 CTLs (antigen-specific CD8
1 T cells) together with natural killer cells are key defenders of host organismsagainst viruses and tumors.
14 CTLs exist as inactive precursor cells in vivo, and they must be activated by specific antigens before differentiation into effector cells. Similar to other T-cell subsets that possess immune activation functions, activated CTLs induce and express high levels of FasL and mediate auto-apoptosis. These mechanisms can prevent the excessive activation of the immune system to sustain systematic immune balance. 15 In Fas-sensitive tumor cells, CTLs can induce tumor cell apoptosis by FasL, which is one of the mechanisms by which CTLs kill tumor cells. 16 It is not clear whether the activation of Fas signaling initiated by FasL on CTLs affects apoptosis-resistant tumor cells. We questioned whether CTLs could improve tumor escape via the activation of Fas-induced non-apoptotic signaling in Fas-resistant tumor cells.
Heterogeneous-population MDSCs comprise granulocytes, macrophages, dendritic cell precursors and myeloid cell precursors in the early differentiation phase. 17 MDSCs inhibit the activation and proliferation of T and natural killer cells, promote the metastasis of tumors, advance the cell cycle and increase the invasive capacity of tumors to mediate tumor escape. [17] [18] [19] [20] [21] [22] [23] A study of tumor patients over the course of clinical therapy revealed that there are large amounts of MDSCs in the peripheral blood and tumor-infiltrating tissues of patients suffering from head and neck cancers, squamous-cell epithelioma, mammary cancer and small-cell lung cancer. After tumor tissues are surgically removed, the number of MDSCs in the peripheral blood of tumor patients decreased. 24 Moreover, after being transferred into tumor tissues, MDSCs differentiated into microvessel tumor endotheliocytes, which can form an environment that is favorable for tumor growth by promoting the generation of tumor neovascularity. 25 These results suggest that the accumulation of MDSCs in tumor tissues is closely related to tumor growth and escape.
However, it remains unknown whether CTLs promote tumor cells to secrete PGE2, increasing tumor cell chemoattraction of MDSCs and thereby leading to tumor escape via Fas signaling. We obtained CTLs expressing high levels of FasL in vitro by stimulating CD8 1 T cells from OT-I mice with the OVA 257-264 peptide and evaluated the functions of Fas signaling activated by FasL-expressing CTLs in tumor tissues. We found that CTLs increased tumor cell chemoattraction of MDSCs by promoting tumor cells to secrete PGE2, which is associated with the activation of the ERK and p38 signaling pathways. This study suggests that activation of tumor Fas signaling driven by FasL on CTLs probably contributes to the accumulation of MDSCs in tumor tissues and promotes the progression of tumor growth. . Female mice at 6-8 weeks of age were bred in a specific pathogen-free facility. The experimental protocols were approved by the Animal Care and Use Committee of the School of Medicine, Zhejiang University (Hangzhou, China).
MATERIAL AND METHODS

Reagents
Phospho-antibodies (Abs) against ERK p44/p42 (ERK1/2, Thr202/Tyr204), JNK/stress-activated protein kinase (JNK/ SAPK, Thr183/Tyr185), p38 (Thr180/Tyr182), NF-kB (Ser536), Stat3 (Tyr705) and corresponding Abs against non-phosphorylated signaling proteins were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-PGE2 Abs (2B5) and cyclooxygenase-2 (COX-2) inhibitor were purchased from Cayman Chemical (Ann Arbor, MI, USA). HRP-coupled secondary Abs and Stat3 inhibitor were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PE-conjugated FasL (CD178) was obtained from eBioscience (San Diego, CA, USA). OVA 257-264 peptides were synthesized by Chinese Peptide Company (Hangzhou, China). NF-kB-, JNK-, p38-and ERK-specific inhibitors were purchased from Calbiochem (San Diego, CA, USA). Preparation and specific cytotoxicity assay of CD8
Plasmid construction
1 T cells CD8 1 T cells were generated as described previously. 4 Briefly, 2310 6 cells/ml lymphocytes from OT-I mice were cultured in RPMI 1640 complete medium and stimulated with or without OVA 257-264 peptide (2 mg/ml) (defined as CTLs and Ctrl T, respectively) for 72 h, and CD8
1 T cells were purified using CD8
1 Dynabeads (Invitrogen, Carlsbad, Cal, USA). The specific cytotoxicity of CD8 1 T cells was assayed as described previously 26, 27 with minor modifications. Briefly, splenocytes from OT-I mice were primed with 10 mg/ml OVA 257-264 peptide as target cells. After 2 h of incubation, the cells were harvested and labeled with 2 mM CFSE. Then, the target cells were mix-cultured with active CD8
1 T cells at different ratios (1 : 0, 1 : 5, 1 : 10 or 1 : 20). The cell mixtures were incubated at 37 uC for 4 h and then labeled with propidium iodide (PI). Finally, the cells were analyzed by FACS, and CFSE 1 cells were gated and collected in equal numbers for each group. CFSE 1 PI 2 cells were counted as living cells, and the specific lysis rate was calculated according to the following formula:
Specific lysis rate (%)5[(negative control group cell count2treatment group cell count)/negative control group cell count]3100%.
Assay for cell chemoattraction
Cell chemoattractionassays were performed in 3.0-mm poresize polyethylene terephthalate track-etched membrane cellculture inserts. The supernatants of 3LL cells co-cultured with CD8
1 T cells were placed below the inserts. Then, CD11b
1 Gr1 1 MDSCs ( 2310 5 ) purified from the spleens of tumor-bearing mice using magnetic beads (MiltenyiBiotec Inc., Auburn, CA, USA) were placed into the transwell inserts. Four hours after incubation at 37 uC, cells that had migrated into the lower chambers were harvested and suspended in 200 ml of phosphate-buffered saline (PBS). PI 2 cells were counted with a FACS Caliburmachine at low rate over 5 min and analyzed with CellQuest software.
Detection of 3LL cell apoptosis and proliferation
Cell apoptosis and proliferation assays were performed to detect whether increased FasL expression on activated CTLs influenced the survival of 3LL cells. Briefly, 50 mg/ml of mitomycin C was used to eliminate the activity of activated CTLs. The inactivated CTLs were cocultured with 3LL cells at indicated ratios (3LL to CTL: 1 : 0.3, 1 : 1 or 1 : 3) for 24 h and were removed with immunomagnetic beads. 3LL cells administered different treatments were then used in the cell apoptosis assay and the proliferation assay.
Immunofluorescence staining and confocal microscopy The distribution of FasL 1 and CD8 1 cells in lymph nodes and tumor tissues was detected by immunofluorescence staining. Frozen sections (8 mm) of tissues from healthy or tumor-bearing mice were fixed in acetone and blocked with PBS containing 3% bovine serum albumin. The samples were sequentially immunostained with Abs against FasL and CD8 and then with DyLight549-and DyLight488-conjugated secondary Abs, respectively. Slides were finally examined under an Olympus FluoView FV1000 confocal microscope and imaged using the Olympus Fluoview version 1.4a viewer (Olympus, Metamora, IL, USA).
RNA interference of Fas and antibody neutralization of FasL
To confirm the chemoattraction of MDSCs to 3LL tumor cells via Fas signaling, we knocked down Fas on 3LL cells with RNA interference and neutralized FasL on CTLs with FasL-blocking Abs. These two cell types were cultured together at the indicated ratios (3LL to CTL: 1 : 0.3, 1 : 1 or 1 : 3), and suspensions of the mixed cultures were collected for the chemoattraction assay. The specific siRNA for Fas or scrambled siRNA were synthesized as follows: Fas siRNA: 59-CUGCUCAGAAGG-AUUAUAUTT-39 and 59-AUAUAAUCCUUCUGAGCAGTT-39, siRNA scramble control: 59-UUCUCCGAACGUGUCAC-GUTT-39 and 59-ACGUGACACGUUCGGAGAATT-39. A standard lipofectamine transfection was performed according to the manufacturer's manual. Twenty-four hours later, the interferential effects were confirmed with real-time PCR. For FasL neutralization, different concentrations of FasL-blocking Abs (5 mg/ml, 10 m g/ml or 20 mg/ml) were added followed by incubation at 37 uC for 2 h to inactivate CTLs.
Cytokine assay PGE2 in the supernatants of cocultured 3LL and CTL cells with different treatments was assayed using ELISA kits according to the manufacturer's instructions (R&D Systems, San Diego, CA, USA).
Reverse transcription PCR and real-time PCR Total cellular RNA was extracted using TRIzol reagent (Invitrogen). Reverse transcription and real-time PCR were performed as described previously. 3 The real-time PCR primers were as follows: COX-2: sense, 59-ACCCGAGGACT-GGGCCATGG-39, antisense, 59-TGCCCCACAGCAAACTG-CAGG-39; b-actin: sense, 59-CGTTGACATCCGTAAAGAC-C-39, antisense, 59-AACAGTCCGCCTAGAAGCAC-39; Fas: sense, 59-AGGAGGCGGGTTCGTGAAACT-39, antisense, 59-TTTGGCTTCTTTACCCACCCCACC-39. 
Statistical analysis
Experimental data were analyzed with one-way ANOVA and ttests using SPSS 11.5. Differences were considered to be significant when the P value was ,0.05.
RESULTS
CTLs have no effect on 3LL tumor cell apoptosis and proliferation To evaluate the expression of FasL on activated CTLs, we isolated lymphocytes from OT-I mice, purified CD8 1 T lymphocytes and stimulated them with OVA 257-264 peptides. After stimulation for 3 days, we found that the CD8 1 T lymphocytes specifically killed splenocytes pulsed with OVA 257-264 , but exhibited no cytotoxic effects against unpulsed splenocytes (Figure 1a , P,0.01). This result demonstrated that we successfully obtained antigen-specific CTLs by stimulating lymphocytes from OT-I mice with OVA 257-264 peptides in vitro. Additionally, we detected the expression of FasL on CTLs by FACS and found that the CTLs were induced to express high levels of FasL (Figure 1b ) and acquired specific cytotoxic functions. We verified that 3LL cells constitutively expressed Fas at the mRNA and protein levels (Figure 1c ). Subsequently, we determined whether CTLs expressing high levels of FasL could induce the apoptosis of 3LL cells by Fas signaling, and we found that these CTLs did not induce the apoptosis of 3LL cells (Figure 1d ). It was reported that Fas signaling can promote tumor cell proliferation. 10, 28 To exclude the possibility that the CTL-induced apoptosis resistance of 3LL cells was not caused by increased proliferation mediated by Fas signaling, we examined 3LL cell proliferation and determined that CTLs did not have an effect (Figure 1e ).
CTLs promote the chemoattraction of MDSCs by 3LL tumor cells via Fas signaling As Fas signaling was shown to promote the recruitment of MDSCs by tumor cells, 12 we examined whether 3LL cells treated with CTLs would result in the chemoattraction of more MDSCs. We cocultured activated CTLs and 3LL cells for 24 h, collected the supernatant and tested its ability to induce the Figure 1 CTLs had no effect on 3LL tumor cell apoptosis and proliferation. 12 Therefore,
we detected changes to COX-2,which is the rate-limiting enzyme in PGE2 synthesis. 29 We found that COX-2 expression was significantly up-regulated at both the mRNA (Figure 3a  and b; Figure 3a , **P,0.01 versus 3LL cells) and protein levels (Figure 3c) . Similarly, in an ELISA assay, we confirmed that the PGE2 levels secreted by 3LL cells treated with CTLs were significantly higher than for non-CTL-treated 3LL cells (Figure 3d , **P,0.001 versus 3LL cells). To confirm the roles of COX-2 and PGE2 in the chemoattraction of MDSCs, we performed experiments to evaluate MDSC chemoattraction by 3LL tumor cells induced by CTLs after COX-2 inhibition or PGE2 blocking, and we found that the COX-2 inhibitor reduced the percentage of MDSCs that were recruited by 3LL tumor cell-mediated chemoattraction ( The increased activation of the p38 and ERK signaling pathways is responsible for the chemoattraction of MDSCs by CTL-treated 3LL tumor cells Next, we investigated which pathway was responsible for the enhanced chemoattraction of MDSCs. Activation of Fas signaling is accompanied by the activation of the MAPK and NF-kB pathways 9, 28, [30] [31] [32] [33] [34] [35] over the course of cell proliferation, tumor metastasis and induction of the inflammatory response, and the activation of Stat-3 in tumor cells is very important in tumor-induced immune tolerance.
18,36 Thus, we detected the expression of phosphorylated ERK, JNK, p38, NF-kB and Stat-3 in 3LL cells after treatment with CTLs. The western blot results demonstrated that CTLs promoted the phosphorylation of ERK, p38, NF-kB and Stat-3, suggesting that CTLs activated the ERK, p38 MAPK, NF-kB and Stat-3 pathways (Figure 4a and b). To confirm the signaling pathway responsible for the chemoattraction of MDSCs by CTL-treated 3LL tumor cells, 3LL tumor cells were pretreated with specific inhibitors for signaling pathways before CTL treatment. Consistent with previous reports, 12 we found that the p38-specific inhibitor SB203580 and the ERK1/2-specific inhibitor U0126 decreased the number of MDSCs recruited via CTL-treated 3LL tumor cell-mediated chemoattraction (Figure 4c , **P,0.01 versus untreated 3LL cells), indicating that CTL activation of the p38 and ERK MAPK signaling pathways was responsible for the increased chemoattraction of MDSCs by CTL-treated 3LL tumor cells. 
CTLs promote increased numbers of MDSCs in
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DISCUSSION
Lung cancer is one of the largest causes of cancer mortality despite current therapy. 37 To eliminate tumor cells, some scientists have attempted to apply immunotherapy. 38 As one of the major components of the antitumor response, adoptive CTL therapy draws much attention; however, its effects are limited, and some malignant cells can survive anticancer therapy. 2, 39 In the tumor microenvironment, complex interactions between CTLs and multiple cell types contribute to immunosuppression. It was found that CTLs that infiltrated tumors recruited MDSC sand triggered a counter-regulatory immunosuppressive mechanism after adoptive CTL lymphocyte therapy for malignancy. 40 The accumulation of MDSCs is caused by IFN-c produced by CTLs. 40 However, it remains unknown whether Fas signaling in tumor cells initiated by FasL on CTLs participates in the CTL recruitment of MDSCs.
In this study, we demonstrated that CTLs expressed high levels of FasL and acquired specific killing functions. The expression of FasL on CTLs mediated the activation of Fas signaling in 3LL tumor cells and induced tumor cells to secrete PGE2, which subsequently increased the ability of 3LL tumor cells to mediate MDSC chemoattraction. Meanwhile, Fas signaling activated the downstream MAPK, NF-kB and Stat-3 pathways in 3LL cells, and the activation of the ERK and p38 pathways was associated with increased MDSC chemoattraction by 3LL tumor cells. These results suggested that CTLs performed tumor killing functions, but the expression of FasL on CTLs induced greater 3LL tumor cell-mediated MDSC chemoattraction through the activation of Fas signaling, thus probably inhibiting CTL tumor killing functions.
CTLs are important effector cells in the elimination of tumor cells. In general, CTLs that infiltrate tumor tissues are in an unresponsive state.
1 During T-cell activation, FasL expression increases on activated CTLs, and this increased FasL expression mediates CTL tumor cell killing and auto-apoptosis. Our previous work demonstrated that exosomes derived from activated T cells promoted tumor invasion via the Fas signaling pathway, 4 indicating that FasL on CTLs possessed the ability to mediate tumor escape. In this study, we found that CTLs induced 3LL tumor cell-mediated MDSC chemoattraction via Fas signaling.
We found that 3LL tumor cells resisted apoptosis induced by high levels of FasL on CTLs, and CTL-treated 3LL tumor cells upregulated COX-2 expression to increase PGE2 secretion, thus resulting in the chemoattraction of more MDSCs. MDSCs are critical mediators of tumor immune suppression and inhibit antitumor immunity through multiple pathways, including the regulation of arginine and tryptophan metabolism through arginase, inducible nitric oxide synthase and indoleamine-2,3-dioxygenase, leading to the suppression of proliferation and CTL functions. 13 COX-2 and PGE2 play an important role in tumor progression. COX-2 is the key regulator of PGE2 synthesis 41 and can depress the immune response and facilitate tumor growth. 42 COX-2 overexpression increases the production of PGE2 to enhance the recruitment of regulatory T cells. 43 PGE2 can promote MDSC recruitment into tumor environments by inducing chemokines such as CXCL12/SDF-1 and CXCR4 and stabilizing the CXCL12 receptor. In addition, PGE2 also induces suppressive factors and directly inhibits T-cell immune responses. 13 Indeed, although Fas induces apoptosis triggered by FasL to maintain systemic homeostasis, as a classic death receptor Fas signaling also exerts non-apoptotic functions under certain conditions. 28 In addition, Fas signaling not only fails to induce tumor cell apoptosis, but also promotes tumor growth by inducing tumor cells to release more PGE2 and enhancing tumor cell recruitment of MDSCs to form an immunosuppressive tumor microenvironment. 12 In this study, we found that CTLs activated tumor cell Fas signaling, which in turn activated MAPK, NF-kB and Stat-3 intracellular signal transduction pathways, leading to 3LL tumor cell resistance to apoptosis induced by CTLs. Our previous work on activated T-cell exosomes showed that FasL 1 exosomes derived from CD8 1 T cells promoted the accumulation of c-FLIP, which was induced by the NF-kB and ERK signaling pathways in B16 tumor cells. 4 Therefore, the difference between these signaling pathways must be further investigated, and it will be worth discerning the molecules that may be involved upstream of MAPK, NF-kB and Stat-3 signaling for this purpose. increased anti-apoptosis proteins, such as FAP-1, in tumor cells, 44, 45 and high levels of c-FLIP inhibit caspase 8 from binding and cleaving the death-inducing signaling complex, leading to Fas-apoptosis resistance in some tumor cells. In addition to inducing tumor cells to release more PGE2 for MDSC chemoattraction, activated CTLs also increase tumor cell invasiveness by upregulating MMP9 via Fas signaling. 7, 9 Therefore, the effects of CTL FasL on tumor escape may be ascribed to multiple functions instead of one single mechanism.
The development of tumors resembles a war between the tumor and the host immune system. At the beginning of tumor development, antitumor-specific CTLs may be induced by tumor-specific antigens or tumor-associated antigens to kill or eliminate tumors. 46 However, FasL expression on CTLs may promote greater MDSC chemoattraction by tumor cells via the activation of Fas signaling to inhibit CTL tumor killing functions. In this study, we learned that in addition to antitumor functions, CTLs facilitate tumor cell evasion of attacks by the immune system. In the tumor microenvironment, tumor cells induce CTLs to lose their tumor killing functions. Higher levels of FasL expression are not only found on activated T cells but also on cancer-associated dendritic cells and macrophages. 47, 48 Similar to CTLs, dendritic cells and macrophages are also important effector cells against tumors. However, based on our discoveries, it can be speculated that dendritic cells and macrophages may be accomplices of CTLs in facilitating tumor escape.
In conclusion, we found that CTLs induced tumor cells to secrete PGE2 and increase tumor cell chemoattraction of MDSCs via Fas signaling, suggesting that CTLs may participate in the process of tumor immune evasion. To our best knowledge, this is a novel mechanism by which CTLs play a role in tumor escape. At the beginning of tumor growth, Fas signaling can recruit MDSCs, but CTLs can still kill tumors. As tumor growth progresses, tumor microenvironments are favorable for tumor escape via the recruitment of more MDSCs to suppress the antitumor functions of CTLs through Fas signaling. Our findings suggest the utility of a strategy to enhance the antitumor immune response by reducing negative tumor immune responses that are promoted by CTLs via Fas signaling.
